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attributable to the institution of Medicare Part D, a national
prescription drug beneﬁt program for the elderly instituted at the
end of 2005 in the United States. METHODS: We implemented
retrospective analyses of pharmacy claims of beneﬁciaries aged
67–79 years from 2005 to 2006, from a large pharmacy chain in
the United States. Subjects aged 61–63 were used a control group
in a differences-in-differences approach to account for trends not
related to Part D. The ﬁnal sample represented approximately
2.4 million unique beneﬁciaries aged 67–79. The main outcomes
are: 1) Changes in proportion of total days of therapy dispensed
as generics, and 2) changes in prescription utilization for each
therapeutic class. RESULTS: Prescription drug use by these ben-
eﬁciaries increased by 11% from 2005 to 2006. After adjustment
for secular trends and other potential confounders, utilization of
each therapeutic class was similar in 2005 and 2006. Small
increases in drug utilization occurred for several drug classes,
ranging from 0.66 pill days (0.46%) for users of nonsteroidal
anti-inﬂammatories (NSAIDs) to 4.64 pill days (1.78%) for users
of angiotensin-converting enzyme (ACE) inhibitors. Decreases
occurred for anti-diabetic drugs (–2.06 pill days, –0.58%), beta-
blockers (–1.24, –0.49%), and benzodiazepines (–5.96 pill days,
–3.57%). Overall, beneﬁciaries were slightly less likely to ﬁll
prescriptions for generic drugs vs. brand-name drugs in 2006
compared to 2005 (OR 0.98, 95% CI 0.97–0.98). CONCLU-
SION: Small increases in prescription drug utilization occurred
across numerous drug classes for these Medicare seniors follow-
ing the implementation of the Medicare Part D Prescription
Beneﬁt, while overall market share by drug class did not change
signiﬁcantly. Further analyses are needed to explore the degree to
which these changes reﬂect moral hazard versus beneﬁcial expan-
sions of coverage.
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PROMOTING A DRUG’S HEALTH ECONOMIC ADVANTAGES IN
MEDICAL JOURNAL ADVERTISING INTHE U.S.:A REVIEW OF
3,500 ADS FROM 1990–2006
Neumann PJ, Palmer JA,Timm AR
Tufts-New England Medical Center, Boston, MA, USA
OBJECTIVES: To quantify and characterize economic-content
in pharmaceutical advertisements, and its supporting evidence,
in leading American medical journals from 1990–2006.
METHODS: Two researchers reviewed all pharmaceutical adver-
tisements in three leading general medical (New England Journal
of Medicine, JAMA, and Annals of Internal Medicine) and spe-
cialty journals (Circulation, Gastroenterology, Neurology) in
three speciﬁed months each year for 2000 through 2006. Using a
standardized data collection form, we investigated economic
claims (e.g., ads using the words “value”, “price”, “savings”,
“hospitalization,” etc.), as well as the supporting evidence. This
work builds upon our previous research of economic claims from
1990–1999, adding new data and content. RESULTS: We
reviewed 3,516 pharmaceutical advertisements (2,144 from
1990–1999 and 1372 from 2000–2006). Economic content
occurred in 11.1% of ads in the 1990s, and 7.6% of ads in
2000–2006 (p = 0.0007). From 1997 to 2002, economic adver-
tisements declined (p < 0.0001), and increased again from 2003–
2006 (p = 0.0006), with a peak in 1997 at 16.2% and a nadir of
3.9% in 2002. Economic claims appeared with similar frequency
in the specialty journal ads across time periods (1990s: 8.6% vs.
2000–2006: 8.5%; p = 0.91), but declined in the general medical
journal ads (1990s: 13.0% vs. 2000–2006: 6.4%; p < 0.0001).
The presence of supporting evidence for economic claims was
similar in the 1990s and 2000s (63.7% vs. 61.5%, p = 0.70), but
over time derived less from the Red Book (1990s: 38.7% vs.
2000–2006: 15.6%) and average wholesale price listings (1990s:
51.1% vs. 2000–2006: 6.3%) and more from data on ﬁle (1990s:
9.5% vs. 2000–2006: 29.7%) and published studies (1990s:
6.6% vs. 2000–2006: 23.4%). From 2000–06, a small number of
ads mentioned patient compliance (2.6%) or persistence (2.0%).
CONCLUSION: Drug companies continue to promote health
economic messages in medical journal advertisements. Mention
of supporting evidence underlying economic claims has not
changed over time, though more ads reference published studies.
PODIUM SESSION III: MUSCULOSKELETAL DISEASE
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IMPACT OF ANTI-TUMOR NECROSIS FACTORS ON HEALTH
CARE RESOURCE UTILIZATION IN PATIENTS WITH
IMMUNE-MEDIATED INFLAMMATORY DISEASES
Tang B1, Rahman MI1, Stephenson JJ2, Quimbo RA2,Thompson HC1,
Naim A1, Dabbous O1
1Centocor, Inc, Horsham, PA, USA, 2HealthCore Inc,Wilmington, DE,
USA
OBJECTIVES: To evaluate the impact of anti-tumor necrosis
factor (anti-TNF) therapy on real world health care resource
utilization in patients with immune-mediated inﬂammatory dis-
eases (IMIDs). METHODS: Three groups of patients were iden-
tiﬁed using claims data from Blue Cross Blue Shield health plans:
IMID (rheumatoid arthritis, ankylosing spondylitis, Crohn’s
disease, psoriatic arthritis, psoriasis or ulcerative colitis) patients
receiving anti-TNF therapy between January 1, 2003 and June
30, 2005 (Group 1); IMID controls without anti-TNF therapy
(Group 2); and non-IMID controls (Group 3). The groups were
matched for gender, age and geographic region in a 3:1 ratio. All
patients had > = 6 months continuous plan enrollment before
and > = 12 months after the index date. Health care resource
utilizations per patient per month (PPPM) were calculated for the
6-month pre- and 12-month post-index periods. Differences from
baseline were compared among three groups. RESULTS: After
matching, 27,006 patients (3,970 Group 1; 11,718 Group 2; and
11,318 Group 3) were analyzed. Of these, 61% were female and
the average age was 46 years. Group 1 had higher pre-index
PPPM resource utilization for all categories than the 2 control
groups. However, compared with pre-index utilization, all post-
index resource utilization categories, except emergency room
visits, showed a signiﬁcant decrease for Group 1 that was not
consistently observed for controls. Inpatient admissions were
reduced in Group 1 (-16.28%), versus no change in Group 2,
and +4.17% for Group 3. Physician visits were reduced in Group
1 (–5.11%) versus +2.73% in Group 2, and +6.24% for Group
3. Non-anti-TNF prescriptions were reduced in Group 1
(-6.70%) versus +6.75% in Group 2, and +8.02% for Group 3.
CONCLUSION: Anti-TNF therapy appears to be associated
with a decrease in health care resource utilization. Additional
analyses to determine the effectiveness of anti-TNF therapies in
patients with IMIDs through clinical, economic, and humanistic
assessments are recommended.
MD2
ECONOMIC CONSEQUENCES OF PROVIDING RITUXIMAB AS
ATREATMENT ALTERNATIVE FOR RHEUMATOID ARTHRITIS
INTHE NETHERLANDS
Pompen M1, Diamantopoulos A2, Kievit W3, Moers R4, Kielhorn A5
1Roche Netherland BV,Woerden,The Netherlands, 2IMS Health,
London, UK, 3Radboud University Nijmegen Medical Centre,
Nijmegen,The Netherlands, 4Roche Nederland BV,Woerden,The
Netherlands, 5F. Hoffmann-La Roche AG, Basel, Switzerland
OBJECTIVES: A pharmacoeconomic analysis was performed to
determine the cost implications of providing rituximab (RTX, a
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selective B cell therapy) + methotrexate [MTX] as an alternative
for the treatment of patients with an inadequate response to
anti-tumour necrosis factor [TNF] therapies in rheumatoid
arthritis [RA] in The Netherlands [NL]. This analysis was per-
formed as part of a reimbursement request. Currently RTX is
reimbursed according to the Dutch Expensive Hospital Drug Act.
METHODS: A cost-effectiveness model was developed to evalu-
ate the societal costs and clinical outcomes of a standard Dutch
treatment sequence either with or without RTX + MTX. The
model uses Monte Carlo simulation to generate 10,000 random
RA patients who start with 2nd line treatment after an inad-
equate response to TNF therapy + MTX. Baseline patient char-
acteristics were taken from the RTX registration study, REFLEX.
Efﬁcacy data were taken from published literature and were
placebo-adjusted to minimise bias from cross-trial comparisons.
Dutch observational data were collected in order to determine
local treatment patterns and resource utilisation data. Both direct
and indirect medical costs were based on ofﬁcial price lists
(2005). Costs and beneﬁts were discounted at 4% and 1.5%,
respectively. RESULTS: The average lifetime treatment costs per
patient in NL were €131,531 for the current treatment sequence
and €141,544 when RTX + MTX was added. QALYs gained
were 3.76 for the current treatment sequence and 4.4 when
RTX + MTX was added. The incremental cost-effectiveness ratio
for inclusion of RTX + MTX in the current treatment sequence
was €13,903/QALY. CONCLUSION: Adding RTX + MTX to
the current treatment sequence is predicted to increase QALYs
with a slight increase in overall lifetime costs for the society.
These favourable outcomes are driven by the lower annual drug
therapy costs compared with other biological alternatives.
MD3
CHANGES IN BODYWEIGHT AND ASSOCIATED DOSING
REQUIREMENTS FOR RHEUMATOID ARTHRITIS PATIENTS
RECEIVING INFLIXIMAB—RESULTS FROM ANALYSIS OFTHE
BRITISH SOCETY FOR RHEUMATOLOGY’S BIOLOGICS
REGISTER (BSRBR)
Gibbons CJ, Morris J,Abhyankar B
Schering-Plough,Welwyn Garden City, UK
OBJECTIVES: To proﬁle the weight change observed in rheuma-
toid arthritis (RA) patients receiving inﬂiximab, in order to
understand the expected change in their dosing requirements
over time on treatment. METHODS: A total 3211 RA patients
(2436 males [24%], 775 females [76%]) with valid bodyweight
and follow-up measurements from the BSRBR were analysed.
Weight change was initially modelled by follow-up (FUP)
number using ordinary least-squares linear regression adjusted
for sex and patient’s total number of visits. Standard errors were
adjusted for clustering on study ID. RESULTS: The main analysis
modelled FUP as a categorical variable. This analysis showed
that the change in average bodyweight did not follow a steady
slope, but rather was characterized by a rapid, statistically sig-
niﬁcant increase of about 1 kg on the ﬁrst visit after baseline
followed by a slow, uneven and statistically nonsigniﬁcant
upward trend over subsequent follow-up visits. This modelling
technique gave a signiﬁcantly better ﬁt (p = 0.006) over that
possible if treating follow-up number as a continuous variable.
To test for possible biases attributable to drop-out, the analysis
was repeated in several subsets of patients who had all completed
the same number of follow-up visits. Despite statistically nonsig-
niﬁcant or statistically borderline estimates in these subsets, the
ﬁndings were similar to those reported in the main results. CON-
CLUSION: Translating observed bodyweight into an expected
number of vials required at each visit using basic 3 mg/kg dosing
shows that the observed weight gain in the BSRBR’s inﬂiximab
patients does not correspond to a statistically signiﬁcant change
in the total number of vials of inﬂiximab required. Although the
dosing in real-life clinical practice tends to vary, the results of this
analysis demonstrate that the weight gain observed during inﬂix-
imab treatment of RA patients is unlikely to have an indepen-
dent, critical impact on the resource implications for these
patients as their treatment continues.
MD4
COST-EFFECTIVENESS OF BONE DENSITOMETRY SCREENING
COMBINED WITH ALENDRONATETHERAPY FORTHOSE
WHO HAVE OSTEOPOROSIS
Hiligsmann M, Bruyère O, Ethgen O, Reginster JY
University of Liège, Liège, Belgium
OBJECTIVES: To evaluate the cost-effectiveness of bone densi-
tometry screening for Belgian women aged 55 and older com-
bined with 5 years Alendronate therapy in osteoporotic women
(femoral neck t-score -2.5) versus no screening and no treat-
ment. METHODS: A microsimulation Markov model was devel-
oped. The model used a lifetime horizon, a Belgian societal
perspective and recorded the full patient history by the use of
tracker variables. Each prior fracture had an impact on transition
probabilities, costs and QALY level. All the model parameters
were selected from Belgian literature when available and from
systematic literature review otherwise. Analyses were realized at
the ages of 55, 60, 65, 70, 75, 80 and 85 years and for women
with 0 to 4 clinical risk factors. Sensitivity analyses were run on
persistence level. RESULTS: Costs per QALY gained for the
screen and treat strategy versus no intervention with optimal
persistence and no clinical risk factor were €49,711, €25,392 and
€10,487 for the ages of 55, 65 and 75 years respectively. With
realistic persistence, these values were respectively €61,373,
€35,780 and €14,302. With one clinical risk factor and optimal
persistence, these values were €31,320, €11,507 and cost-saving.
And with two clinical risk factors, these values were €18,206,
€2,588 and cost-saving. CONCLUSION: Universal bone densi-
tometry followed by Alendronate treatment in the presence of
osteoporosis seems highly cost-effective (cost per QALY gained
€30,000) for women aged 65 and older (with optimal persis-
tence), for women aged 70 and older (with realistic persistence)
and for women with at least one clinical risk factor aged 60 or
older (even under realistic persistence assumption). We con-
cluded that screening individuals with or more clinical risk
factors is more cost-effective than universal screening and should
be recommended.
PODIUM SESSION IV: CARDIOVASCULAR DISEASE II
CV5
FONDAPARINUX (FOND)VERSUS ENOXAPARIN (ENOX) FOR
PREVENTION ANDTREATMENT OFVENOUS
THROMBOEMBOLIC EVENTS (VTE) IN PATIENTS
UNDERGOING MAJOR ORTHOPEDIC SURGERY OFTHE
LOWER LIMBS (MOSLL) IN GERMANY: ECONOMIC
EVALUATION FROMTHE HOSPITAL PERSPECTIVE
Schaedlich P1, Briswalter S2, Brecht J3
1Informed, Itzehoe, Germany, 2GlaxoSmithKline, Munich, Germany,
3Informed, Ingolstadt, Germany
OBJECTIVES: To estimate, from the hospital perspective, the
cost effectiveness of FOND versus ENOX for prevention and
treatment of VTE in MOSLL patients in Germany (42% with
total hip replacement, 33% with total knee replacement, 25%
with hip-fracture surgery). METHODS: The incremental cost-
effectiveness ratio ‘additional cost for FOND per clinical VTE
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